• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

作者信息

Catapano Alberico L, Reiner Zeljko, De Backer Guy, Graham Ian, Taskinen Marja-Riitta, Wiklund Olov, Agewall Stefan, Alegria Eduardo, Chapman M John, Durrington Paul, Erdine Serap, Halcox Julian, Hobbs Richard, Kjekshus John, Filardi Pasquale Perrone, Riccardi Gabriele, Storey Robert F, Wood David

机构信息

Department of Pharmacological Science, University of Milan, Milano, Italy.

出版信息

Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028.

DOI:10.1016/j.atherosclerosis.2011.06.028
PMID:21882396
Abstract
摘要

相似文献

1
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理指南 血脂异常管理特别工作组
Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028.
2
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理特别工作组
Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012.
3
The new joint EAS/ESC guidelines for the management of dyslipidaemias.欧洲动脉粥样硬化学会（EAS）/欧洲心脏病学会（ESC）血脂异常管理联合新指南。
Atherosclerosis. 2011 Jul;217(1):1. doi: 10.1016/j.atherosclerosis.2011.06.011. Epub 2011 Jun 30.
4
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组编写，欧洲心血管预防与康复协会（EACPR）提供特别贡献。
Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.
5
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
6
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南。
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
7
[ECS guidelines 2016 - dyslipidaemias].[2016年欧洲心脏病学会血脂异常指南]
Herz. 2016 Dec;41(8):671-676. doi: 10.1007/s00059-016-4505-6.
8
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).2014年欧洲心脏病学会/欧洲麻醉学会非心脏手术心血管评估和管理指南：非心脏手术心血管评估和管理联合工作组：欧洲心脏病学会（ESC）和欧洲麻醉学会（ESA）
Eur J Anaesthesiol. 2014 Oct;31(10):517-73. doi: 10.1097/EJA.0000000000000150.
9
[The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].[2013年美国心脏病学会/美国心脏协会关于降低动脉粥样硬化性心血管风险的血脂治疗新指南：与欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理建议的比较]
G Ital Cardiol (Rome). 2014 Jan;15(1):19-20. doi: 10.1714/1394.15514.
10
[A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].[欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南及欧洲临床实践心血管疾病预防指南发布后的降脂治疗展望]
Turk Kardiyol Dern Ars. 2012 Jun;40(4):293-7. doi: 10.5543/tkda.2012.83873.

引用本文的文献

1
Treatment Pathways and Outcomes in Patients with BMI ≥ 50 kg/m: Conservative Treatment, Immediate Surgery or Stepwise Surgical Approach.体重指数（BMI）≥50kg/m²患者的治疗途径与结局：保守治疗、即刻手术或逐步手术方式
Obes Surg. 2025 Jul 18. doi: 10.1007/s11695-025-08102-1.
2
Effects of Personalized Nutrition Education on Lipid Profiles in Chinese Adults: A Medical Student-Implemented Community Intervention Study.个性化营养教育对中国成年人血脂谱的影响：一项由医学生实施的社区干预研究。
Nutrients. 2025 Jun 28;17(13):2161. doi: 10.3390/nu17132161.
3
Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis.
类风湿关节炎患者新型心血管风险计算器的评估
J Rheum Dis. 2025 Apr 1;32(2):145-147. doi: 10.4078/jrd.2024.0093. Epub 2024 Oct 8.
4
Comparison of atherogenic indices for predicting the risk of metabolic syndrome in Southwest Iran: results from the Hoveyzeh Cohort Study (HCS).伊朗西南部用于预测代谢综合征风险的致动脉粥样硬化指数比较：霍韦泽队列研究（HCS）结果
Diabetol Metab Syndr. 2024 May 23;16(1):112. doi: 10.1186/s13098-024-01349-1.
5
Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study.胸痛住院患者家族性高胆固醇血症的患病率及管理：一项回顾性观察研究。
BMJ Open. 2024 Feb 22;14(2):e082075. doi: 10.1136/bmjopen-2023-082075.
6
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.基于依洛尤单抗的 LDL-C 管理在德国临床实践中的高和极高心血管风险患者中的应用：HEYMANS 研究。
Adv Ther. 2024 Mar;41(3):1184-1200. doi: 10.1007/s12325-023-02757-x. Epub 2024 Jan 30.
7
Potential Prognostic Relevance of Left-Ventricular Global Longitudinal Strain and of the Summation of the Mitral and Tricuspid Regurgitation Volume in Patients with Non-Ischemic Dilated Cardiomyopathy.左心室整体纵向应变及二尖瓣与三尖瓣反流容积总和在非缺血性扩张型心肌病患者中的潜在预后相关性
J Cardiovasc Dev Dis. 2023 Sep 27;10(10):410. doi: 10.3390/jcdd10100410.
8
The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease.富含甘油三酯的脂蛋白及其残粒在动脉粥样硬化性心血管疾病中的作用
Eur Cardiol. 2023 Sep 28;18:e56. doi: 10.15420/ecr.2023.16. eCollection 2023.
9
Stearic Acid, but not Palmitic Acid, is Associated with Inflammatory and Endothelial Dysfunction Biomarkers in Individuals at Cardiovascular Risk.硬脂酸与心血管风险个体的炎症和内皮功能障碍生物标志物相关，而棕榈酸则没有。
Arq Bras Cardiol. 2023 Sep 1;120(8):e20220598. doi: 10.36660/abc.20220598. eCollection 2023.
10
Acute Pancreatitis as an Unusual Culprit of Diabetic Ketoacidosis in a Nondiabetic: A Case-Based Review.急性胰腺炎作为非糖尿病患者糖尿病酮症酸中毒的罕见病因：基于病例的综述
Case Rep Endocrinol. 2023 Aug 22;2023:9122669. doi: 10.1155/2023/9122669. eCollection 2023.